INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1401, 21936, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1402, 24268, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1403, 26314, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1404, 26558, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1405, 26559, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1406, 26940, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1407, 26941, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1408, 28349, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1409, 28350, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1410, 29588, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1411, 30215, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1412, 30833, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1413, 30834, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1414, 31823, 'Atorvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.  Active liver disease or unexplained transaminase elevations are contraindications to statin use.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1415, 1088, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1416, 1089, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1417, 1090, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1418, 1094, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1419, 1095, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1420, 1097, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1421, 1678, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1422, 4008, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1423, 4009, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1424, 4735, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1425, 7349, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1426, 7350, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1427, 7352, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1428, 7355, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1429, 7359, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1430, 7372, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1431, 7397, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1432, 7398, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1433, 7399, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1434, 11556, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1435, 13234, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1436, 13512, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1437, 14227, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1438, 14228, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1439, 14563, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1440, 14570, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1441, 15442, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1442, 16266, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1443, 18869, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1444, 21870, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1445, 21882, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1446, 21884, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1447, 21885, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1448, 21887, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1449, 21889, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1450, 21890, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1451, 21891, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1452, 21893, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1453, 21894, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1454, 21905, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1455, 21906, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1456, 21907, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1457, 21915, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1458, 21916, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1459, 21935, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1460, 21936, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1461, 24268, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1462, 26314, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1463, 26558, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1464, 26559, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1465, 26940, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1466, 26941, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1467, 28349, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1468, 28350, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1469, 29588, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1470, 30215, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1471, 30833, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1472, 30834, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1473, 31823, 'Atorvastatin', 'Coadministration with grapefruit juice may increase the plasma concentrations of atorvastatin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients receiving therapy with atorvastatin should limit their consumption of grapefruit juice to no more than 1 liter per day.  Patients should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.  In addition, patients should either refrain from the use of oat bran and pectin or, if concurrent use cannot be avoided, to separate the administration times by at least 2 to 4 hours.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1474, 0, 'Oliceridine', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oliceridine.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oliceridine.  Any history of alcohol or illicit drug use should be considered when prescribing oliceridine, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oliceridine should preferably avoid the consumption of grapefruit and grapefruit juice.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1475, 52, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1476, 3412, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1477, 4370, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1478, 7103, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1479, 9189, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1480, 10592, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1481, 12958, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1482, 12959, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1483, 12960, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1484, 13619, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1485, 14176, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1486, 15293, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1487, 16782, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1488, 18830, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1489, 19774, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1490, 19808, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1491, 20891, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1492, 20892, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1493, 21605, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1494, 23998, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1495, 23999, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1496, 24000, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1497, 24002, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1498, 25222, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1499, 26604, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1500, 26605, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1501, 26606, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1502, 30056, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1503, 30057, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1504, 30059, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1505, 30190, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1506, 30191, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1507, 32234, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1508, 32301, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1509, 32302, 'Olanzapine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1510, 0, 'Omadacycline', 'Administration with food, particularly dairy products, may reduce the absorption of omadacycline.  The calcium content of these foods may form nonabsorbable chelates with omadacycline.', 'dairy products', 'Moderate', 'Omadacycline should be administered at least 2 hours before (4 hours for dairy products) or 4 hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1511, 22141, 'Olaparib', 'Grapefruit juice may significantly increase the plasma concentrations of olaparib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1512, 22142, 'Olaparib', 'Grapefruit juice may significantly increase the plasma concentrations of olaparib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1513, 0, 'Opicapone', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1514, 0, 'Opicapone', 'Food may reduce the rate and extent of absorption of opicapone.  When opicapone was administered following a moderate fat/moderate calorie meal, mean opicapone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 62% and 31%, respectively, while the time to reach peak concentration (Tmax) was delayed by 4 hours.', 'high-fat foods', 'Moderate', 'Patients should avoid eating 1 to 2 hours before and after taking opicapone.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1515, 1116, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1516, 1117, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1517, 11376, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1518, 12144, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1519, 20934, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1520, 20935, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1521, 30164, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1522, 30165, 'Opium', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1523, 8977, 'Orphenadrine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1524, 23709, 'Orphenadrine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1525, 0, 'Ospemifene', 'Food significantly enhances the oral bioavailability of ospemifene.  In a cross-study comparison, administration of a single 60 mg dose of ospemifene with a high-fat/high-calorie meal (860 kcal) in postmenopausal women increased ospemifene peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.3- and 1.7-fold, respectively, compared to administration under fasted condition.', 'high-fat foods', 'Moderate', 'Ospemifene should be taken once daily with food.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1526, 521, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1527, 522, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1528, 609, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1529, 610, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1530, 611, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1531, 612, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1532, 4968, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1533, 4985, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1534, 4986, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1535, 4988, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1536, 4989, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1537, 5008, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1538, 5012, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1539, 5014, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1540, 5015, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1541, 6085, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1542, 13988, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1543, 13990, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1544, 13991, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1545, 13992, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1546, 16673, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1547, 16939, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1548, 16940, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1549, 18789, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1550, 19197, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1551, 19218, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1552, 19222, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1553, 19225, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1554, 20036, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1555, 24655, 'Oxacillin', 'Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food.  The therapeutic effect of the antimicrobial may be reduced.', 'food', 'Moderate', 'The interacting penicillin should be administered one hour before or two hours after meals.  Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1556, 24385, 'Oxaprozin', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1557, 24386, 'Oxaprozin', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1558, 1109, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1559, 1110, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1560, 1111, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1561, 6629, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1562, 14591, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1563, 14592, 'Atropine', 'Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous.  In addition, the potential for abuse may be increased with the combination.  The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.', 'alcohol', 'Moderate', 'Alcohol should generally be avoided during therapy with anticholinergic agents.  Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1564, 9475, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1565, 9476, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1566, 11669, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1567, 11672, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1568, 14143, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1569, 14144, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1570, 24370, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1571, 24387, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1572, 24388, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1573, 24400, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1574, 26920, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1575, 26921, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1576, 26922, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1577, 28508, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1578, 28511, 'Oxcarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1579, 9483, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1580, 16680, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1581, 16681, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1582, 24395, 'Oxazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1583, 0, 'Oxymorphone', 'Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Moderate', 'Concomitant use of opioid analgesics with ethanol should be avoided.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1584, 0, 'Ozanimod', 'Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with ozanimod.  The mechanism is inhibition of monoamine oxidase type A (MAO-A) by metabolites of ozanimod.  MAO-A is the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact.  Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules.', 'Tyrosine-rich foods', 'Major', 'In general, patients treated with ozanimod should avoid consumption of products that contain large amounts of amines (e.g., tyramine) and protein foods in which ageing or breakdown of protein is used to increase flavor.  These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements.  Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well.  At least 14 days should elapse following discontinuation of ozanimod therapy before these foods may be consumed.  Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned.  Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1585, 8130, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1586, 20677, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1587, 20678, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1588, 20679, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'high-fat foods', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1589, 8130, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1590, 20677, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1591, 20678, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1592, 20679, 'Palbociclib', 'Administration with food may enhance the oral bioavailability of palbociclib in some patients and reduce the intersubject variability of palbociclib exposure.  According to the product labeling, palbociclib absorption and exposure were very low in approximately 13% of the population when taken in the fasted state.  Food intake increased the palbociclib exposure in this small subset of the population, but did not alter palbociclib exposure in the rest of the population to a clinically relevant extent.  Compared to palbociclib given under overnight fasted conditions, the population average palbociclib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 38% and 21%, respectively, when given with high-fat, high-calorie food (approximately 800 to 1000 calories; 150, 250, and 500 to 600 calories from protein, carbohydrate and fat, respectively).', 'grapefruit juice', 'Moderate', 'Patients should take palbociclib with food and avoid consumption of grapefruit or grapefruit juice during treatment.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1593, 151, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1594, 11330, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1595, 11336, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1596, 11338, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1597, 11339, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1598, 11340, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1599, 27721, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);
INSERT OR REPLACE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (1600, 28086, 'Oxytetracycline', 'Administration with food, particularly dairy products, significantly reduces tetracycline absorption.  The calcium content of these foods forms nonabsorbable chelates with tetracycline.', 'dairy products', 'Moderate', 'Tetracycline should be administered one hour before or two hours after meals.', '', '', 'DDInter', 0);